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ABSTRACT 
Mixed Suspension-Mixed Product Removal (MSMPR) crystallizers are widely implemented for the 
continuous crystallization of active pharmaceutical ingredients (APIs), allowing enhanced efficiency, 
flexibility and product quality compared to the currently dominant batch crystallizer designs. 
Establishing cost-effective continuous crystallization process configurations for societally- and 
economically-important APIs is essential to ensure the successful implementation of fully end-to-end 
continuous pharmaceutical manufacturing (CPM) campaigns. Process modelling and optimization 
allow rapid, systematic comparison of technoeconomic evaluations. This paper pursues total cost 
minimization of different crystallizer configurations of three APIs, cyclosporine, paracetamol and 
aliskiren hemifumarate, whose continuous MSMPR crystallization has been experimentally 
demonstrated. Nonlinear optimization for total cost configuration is implemented for 1-3 crystallizers 
for different plant API capacities with crystallizer temperatures and residence times as decision 
variables. Optimization results show that the optimal number of crystallizers is dependent on plant 
capacity; implementing one crystallizer is preferred for all three APIs at 102 kg y-1, whilst multiple 
crystallizer implementation is more cost-beneficial at increased capacities. These trends are observed 
due to the increasing dominance of operating expenditures on total costs at increased capacities, 
making the benefits of implementing more crystallizers (enhanced yields, reduced utility loads) worth 
the increased capital expenditures. Process modelling and optimization allows rapid technoeconomic 
evaluation of MSMPR crystallizer configurations for different APIs towards systematic selection of 
optimal continuous crystallizer designs for pharmaceutical manufacturing. 
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1. Introduction 
Continuous pharmaceutical manufacturing (CPM) has received significant attention from academia, 
industry and regulatory bodies1 due to its potential for significant operational2 and economic3 benefits 
in comparison to traditionally implemented batch methods.4 The wide variety of continuous flow 
synthetic route demonstrations5–9 and integrated end-to-end CPM processes being implemented for 
pilot plant,10 portable reconfigurable units11 and production level processes12,13 shows the beginning of 
the transition from batch to CPM in industry. While continuous flow syntheses of promising active 
pharmaceutical ingredients (APIs) are the foundation of CPM, establishing reliable continuous 
separation processes is paramount for successful end-to-end continuous manufacturing.14 
A significant portion of pharmaceutical products are sold as solids (tablets, dispersions, gels or 
topical treatments), and thus crystallization is an essential unit operation in drug product 
manufacturing. Traditional batch crystallization techniques are widely studied and well understood, 
but batch-to-batch variability may induce deviations from product specifications regarding crystal 
product quality attributes, which leads to significant quantities of waste.15 Continuous crystallization 
has received attention for its potential to increase flexibility, efficiency and quality.16 
The mixed suspension, mixed product removal (MSMPR) crystallizer is a widely studied 
continuous crystallizer design due to its simple operation, low maintenance requirements, avoidance 
of rapid fouling typical of continuous solids processes and tubular crystallizer designs17 and ease of 
adaptation from existing batch stirred tanks.16 Recent work using MSMPRs for crystallization kinetic 
parameter estimation,18–21 comparison of operating strategies, process configurations and control,22–34 
novel crystallization techniques,35–38 specialized separations39–46 and polymorph selectivity47,48 have 
significantly developed MSMPR implementation, with some designs integrated into end-to-end CPM 
plants.10,49 However, continuous crystallizer designs operate at steady-state and thus do not reach 
equilibrium, leading to potentially lower yields compared to batch processes; establishing technically 
feasible and economically viable operating parameters for continuous designs is essential for the 
successful transition from batch to continuous crystallization methods.  
Investigation of continuous processes for APIs of economic significance to the pharmaceutical 
industry is important to realize the technoeconomic benefits attainable via CPM. Several 
pharmaceutical compounds have been investigated for their MSMPR crystallization in the literature, 
including the APIs: cyclosporine, an immunosuppressant with applications for skin ailment treatment 
(namely psoriasis) and rheumatoid arthritis, paracetamol, the popular analgesic, and aliskiren 
hemifumarate, a renin inhibitor for the treatment of primary hypertension. Historic and predicted 
revenues for prescription hypertensive50 and non-prescription analgesics and skin treatment 
medicines51 (Figure 1) and their multiple formulation types (Table 1) illustrate the societal and 
economic importance of these APIs in the pharmaceutical industry. The optimal design of continuous 
crystallization processes for their integration into CPM campaigns is paramount.  
 
 
Figure 1: Historical and predicted US revenues for prescription hypertension (aliskiren) and non-
prescription analgesic (paracetamol) and skin treatment (cyclosporine, psoriasis) drugs. 
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Table 1: Brands and formulations of cyclosporine, paracetamol and aliskiren.  
API Application Brand Name Prescription? Patented? Formulation 
Cyclosporine 
Immunosuppressant 
Sandimmune® ✓ ✓ 
Oral capsule 
Oral solution 
Intravenous solution 
Cicloral® ✓ X Oral capsule 
Deximune® ✓ X Oral capsule 
Psoriasis Neoral® ✓ ✓  Oral capsule 
Oral solution 
Rheumatoid arthritis Neoral® ✓ ✓  Oral capsule 
Oral solution 
Keratoconjunctivitis Restasis® ✓ ✓ Ophthalmic emulsion
Paracetamola Analgaesic 
Tylenol® X X Oral tablet 
Calpol® X X Oral suspension 
Panadol® X X Oral tablet 
Aliskiren Hypertension Tekturna
® ✓ ✓ Oral tablet 
Rasilez® ✓ ✓ Oral tablet 
 
Continuous crystallization design must be cost-effective; while various studies have optimized 
MSMPR configurations to maximize yield and purity, technoeconomic optimization to establish 
viable MSMPR process configurations has yet to be widely conducted.52–55 Process modelling and 
optimization are useful tools for rapid technoeconomic evaluations of candidate designs;56 doing so 
for societally important APIs with high sales volumes is essential for successful demonstration of 
continuous crystallizer configurations prior to pilot plant implementation and scale up. 
This work conducts total cost minimization by nonlinear optimization of different MSMPR 
cascades for cyclosporine, paracetamol and aliskiren hemifumarate. First, we describe the continuous 
crystallization process implemented for all three APIs. Subsequently, we describe the process model, 
costing methodology and the constrained nonlinear optimization problem formulation for total cost 
minimization. We then present minimal total cost components for all APIs for varying numbers of 
crystallizers and different plant API capacities with corresponding optimal design parameters of the 
implemented crystallizers. 
 
2. Process Modelling and Nonlinear Optimization Methodology 
2.1 Process Flowsheet 
The process investigated here is the continuous MSMPR crystallization of cyclosporine, paracetamol 
and aliskiren (hemifumarate), whose relevant physical properties are listed in Table 2. The process 
flowsheet for a cascade of MSMPR crystallizers in series for continuous crystallization based on 
experimental demonstrations19,20,38 is shown in Figure 2. A mother liquor stream containing dissolved 
API enters the first crystallizer, whose product magma is the feed stream to the subsequent crystallizer 
in the cascade. Crystallization occurs by cooling only, without the need for an antisolvent to generate 
supersaturation.19,20,38 Experimental setups for the MSMPR crystallization of cyclosporine, 
paracetamol and aliskiren have shown that configurations with no recycle are efficient in terms of 
both yield and purity. MSMPR studies investigating mother liquor recycle options for cyclosporine 
showed that increasing recycle ratios lead to increasing accumulation of impurity in the crystalline 
product. Solids recycle options for the MSMPR crystallization of cyclosporine24 were shown to be 
economically inferior to those without recycle due to significant API losses in purge streams required 
to maintain steady-state operation, which had a detrimental effect on plantwide API yield and total 
costs.57 Throughout this study, we model a series of MSMPR crystallizers without recycle (Figure 2). 
         Cyclosporine is crystallized by cooling from a mother liquor solvent of acetone;38 paracetamol is 
crystallized from a 4:1 mixture (volume basis) of isopropanol:water;19 aliskiren hemifumarate is 
crystallized from a 1:1 mixture of ethyl acetate:ethanol (mass basis).20 The experimental 
demonstration of aliskiren hemifumarate crystallization describes a reactive crystallization step 
performed at 20 °C prior to cooling crystallization,20 which is assumed to be conducted prior to the 
process considered here. The cascade consists of N = 1-3 crystallizers. We consider plant API 
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capacities (QAPI) of 102, 103 and 104 kg API per year to investigate the effects of production scale, 
which can significantly affect the economic viability of modelled CPM designs.58 Varying design 
capacities (QAPI) considered here do not signify a range of capacities implemented for a single plant; 
they are considered for separate plant designs to comparatively illustrate the effect of capacity on 
relevant cost components and their relative contribution to total plant costs. The considered plant 
capacities, QAPI = {102, 103, 104} kg API y-1 are justified since continuous processing technologies are 
yet to be widely implemented in pharmaceutical manufacturing, hence a CPM process may first be 
implemented at a rather small production scale, beyond the published literature demonstration cases. 
Three different capacities have been compared here for each API, to illustrate the effect of capacity on 
cost-optimal design and operating parameters, and its relative influence on individual category 
contributions to total cost. For the considered plant capacities, QAPI = {102, 103, 104} kg API y-1, we  
explore the effect of allowing one, two and three MSMPR crystallizers for CPM implementation, a 
range consistent with our recently published study.57 Crystallizer operating temperatures are between 
–10 and 20 °C, and the maximum total cascade residence is 15 h. Concentrations of dissolved API in 
mother liquor feed streams (C0) vary according to experimental procedures;19,20,38 cyclosporine, 
paracetamol and aliskiren feed concentrations of 25, 8.86 and 6% w/w, respectively, are assumed. 
 
 
Figure 2: Process flowsheet of a cascade of continuous MSMPR crystallizers. 
This work considers MSMPR cascades for continuous cooling crystallization with no antisolvent 
usage, recycle implementation or up-/downstream requirements considered to affect the process. In 
practice, distribution of impurities from upstream unit operations is an important consideration in 
crystallization operating parameter selection and its effects on downstream processing requirements. 
We assume that fresh mother liquor feed streams contain negligible amounts of impurity that will 
affect the attained crystal purities in these processes, due to uncertainties in crystallization feed stream 
compositions. Knowledge of typical crystallization feed stream compositions in integrated CPM 
processes will greatly enhance the understanding of impurity distributions on optimal continuous 
crystallization process designs for the APIs studied here. 
Table 2: Physical properties of cyclosporine, paracetamol and aliskiren.  
API Formula CAS # MW  
(g mol-1) 
Density, ρAPI 
(g mL-1) 
Melting Point 
(°C) 
Cyclosporine C62H111N11O12 59865-13-3 1,206.61 1.30 150 
Paracetamol C8H9NO2 103-90-2    151.16 1.33 169 
Aliskiren C30H55N3O6 173334-57-1    551.76 1.20   99 
2.2 Steady-State Process Model 
MSMPR crystallization assumes a clear, homogeneous feed mother liquor stream containing no 
crystals. All crystallizers operate at steady-state; product magmas exit all crystallizers at equilibrium 
and have the same composition as the crystallizer contents (i.e., crystallizer contents are perfectly 
mixed). No crystal breakage or attrition occurs and crystal growth is assumed linear (one-
dimensional) and size-independent. The steady-state process model describes crystallisation kinetics, 
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API solubilities, crystal population balances and process mass balances; the simultaneous solution of 
these equations describes continuous MSMPR crystallization. The model is solved in MATLAB, 
implementing the same methodology and solver settings as described in our previous publication.57 
2.2.1 Crystallization Kinetics 
Crystal growth and nucleation kinetics are described by Arrhenius-type power law expressions. 
Gi	=	kg0 expቆ– EagRሺTi	+	273.15ሻቇ ቆ
Ci
Ci
sat – 1ቇ
g
 (1)
Bi = kb0 expቆ– EabR(Ti + 273.15ሻ
ቇ ቆ Ci
Ci
sat – 1ቇ
b
Mi
 m (2)
Here, Gi and Bi are the crystal growth and nucleation rates in MSMPR i operating at temperature Ti, 
respectively. Ci and Csat,i are the API equilibrium (outlet) and saturation (solubility) concentrations at 
Ti, respectively. Mi is the slurry density in MSMPR i. Growth kinetic parameters are kg0, the growth 
pre-exponential factor, Eag, the growth energy barrier, and g, the growth exponent. Nucleation 
parameters are kb0, the nucleation pre-exponential factor, Eab, the nucleation energy barrier, b, the 
nucleation exponent, and m, the slurry density exponent. Temperature-dependency of crystal 
nucleation for paracetamol and aliskiren has not been considered in the literature,19,20 and thus Eab for 
these APIs equals zero. Similarly, m for aliskiren is considered equal to zero.20 The units of kb0 for 
paracetamol available in the literature are not consistent with the developed process model,57 so the 
value of Bi for paracetamol crystallization processes must be converted from mass- to volume-based 
units. Crystallization kinetic parameters from the literature for all APIs are summarized in Table 3. 
Table 3: Steady-state process model parameters for continuous MSMPR crystallization. 
API Cyclosporine (C62H111N11O12) Paracetamol (C8H9NO2) Aliskiren (C30H55N3O6) 
 Value Units Value Units Value Units 
kg0 1.13 · 107 m min-1 2.00 · 10-2  m min-1 2.9 · 10-4 m min-1 
Eag/R 9.06 · 103 K 1.73 · 103 K 3.5 · 102 K 
g 1.33 – 1.08 – 1.08 – 
kb0 4.80 · 1020 # crystals m-3 min-1 295 # crystals kg-1 s-1 3.2 · 107 # crystals m-3 min-1 
Eab/R 7.03 · 103 K 0 K 0 K 
b 1.50 – 2.14 – 1.95 – 
m 2/3 – 1.62 – 0 – 
kv π/6 – 0.61 – 0.04 – 
Solubilities of APIs (i.e., API saturation concentrations, Csat,i) as a function of temperature are 
required for accurate description of crystallization kinetics. Saturation concentrations as a function of 
temperature are described as temperature-dependent polynomials regressed from experimental 
solubility data for cyclosporine,31,57 paracetamol,19 and aliskiren.20 
Ci,sat  = (1.17 · 10-4)Ti2 + (2.00 · 10-4)Ti + 0.05                                          for (3)
Ci,sat = (3.79 · 10-2)Ti2 + (3.77 · 10-1)Ti + 0.21                                          for paracetamol (4)
Ci,sat = (7.60 · 10-7)Ti3 – (3.20 · 10-5)Ti2 + (5.20 · 10-4)Ti + (4.50 · 10-3)   for aliskiren (5)
2.2.2 Population Balance Equations 
The general one-dimensional population balance model is described by a system of ordinary 
differential equations (ODEs). 
G1V1
dn1
dL
 = –F1n1 (6)
GiVi
dni
dL
	= Fi–1ni–1–Fini i = 2 … N.                                                                           (7)
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Vi is the volume of MSMPR i, Fi-1 and Fi are the volumetric flowrates of streams entering and 
leaving MSMPR i, respectively (Figure 2), N is the number of crystallizers in the cascade, ni is the 
crystal population density and L is the characteristic (one-dimensional) length of the crystal. 
Population balance equations are satisfied by the boundary condition ni0 = ni(L = 0), corresponding to 
the crystal nuclei population density. 
ni
0	=	 Bi
Gi
 (8)
The slurry density, Mi, is calculated from the population density (eq. 9). 
Mi	=	kv	ρAPI න niL3dL (9)
kv is the crystal volume shape factor59–61 and ρAPI is the API crystal density; values for all APIs are 
listed in Tables 2 and 3. 
2.2.3 Process Mass Balances 
The steady-state mass balances for each process assume no material accumulation and account for 
volumetric changes due to solid formation due to API crystallization. 
F0C0	–F1 ቆ1	–	 M1ρAPI
ቇC1 –	F1M1	=	0 (10)
Fi–1 ൬1	–	Mi–1ρAPI൰Ci–1 + Fi–1Mi–1	–Fi ൬1	–	
Mi
ρAPI
൰Ci –FiMi ൌ 0             i = 2 … N. (11)
F0 and C0 are the fresh feed volumetric flowrate and mother liquor API concentration to the first 
crystallizer, respectively. An API balance across mother liquor and crystallised solid phases also gives 
the following expression for the slurry density from the process mass balances. 
Mi	=	Ci–1	–Ci (12)
2.2.4 Crystallization Yield 
The crystallization yield is calculated from the mother liquor API concentration exiting the final 
crystallizer relative to the API concentration in the feed stream to the first crystallizer. 
Ycryst	=	100 ൬1	–	CNC0൰ 
(13)
2.2.5 Crystallizer Volumes 
Crystallizer volumes are calculated from the specified residence time (τi) and the volumetric flowrate 
through the crystallizer. 
Vi	=	Fiτi	 (14)
2.2.6 Costing Methodology 
We implement an established methodology for costing pharmaceutical manufacturing processes.3 All 
crystallization cascade designs are assumed to be implemented at an existing pharmaceutical 
manufacturing site with essential auxiliary structures already in place; for the capacities considered 
here (QAPI = 102, 103, 104 kg API y-1), construction of a dedicated facility is unlikely, and so this is a 
reasonable assumption. Annual operation of 8,000 hours is considered.  
Prices for equipment of similar capacities to those considered here have been sourced where 
possible; where such data is unavailable, the following cost-capacity correlation is used.62 
PB	=	f	PA ൬
SB
SA
൰
n
 (15)
Pj is the equipment purchase cost at capacity Sj. Parameters n and f are equipment-dependent and can 
be found in the literature.63 Wherever the reference purchase cost (PA) is taken from the past, chemical 
engineering plant cost indices (CEPCIs) are used to calculate the corresponding present purchase cost 
in the present day. All equipment capacities are scaled to account for plantwide inefficiencies to meet 
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the specified plant capacity. Table 4 gives details for the purchase costs and scaling parameters in eq. 
15 for each equipment item. 
 
Table 4: Equipment parameters for calculating scaled equipment purchase costs in the present day (eq. 15). 
Item Ref. Year Ref. Cost, PA 
(GBP) 
Capacity Basis Ref. Capacity, SA n f  
(%) 
Ref.
Crystallizer 2007 328,875 m3 3.00 0.53 10.33 (61)
Pump 2015        958 – – 1.00 – (62)
Cooler 2007     3,454 – – 1.00 – (61)
The sum of all inflation-adjusted equipment costs (PB) gives the Free-on-Board (FOB) cost. The 
Chilton method is used to calculate the Battery Limits Installed Cost (BLIC).64 The installed 
equipment cost (IEC), process piping and instrumentation (PPI) and total physical plant cost (TPPC) 
are calculated from eqs. 16-18. A construction factor of 30% is added to TPPC to calculate the BLIC 
(eq. 19).3 
IEC = 1.43FOB (16)
PPI = 0.42IEC (17)
TPPC = IEC + PPI (18)
BLIC = 1.3TPPC (19)
Working capital and contingency costs (WCC) are calculated as follows. Working capital (WC) 
costs are taken as 3.5% of annual material (mother liquor solvent) costs (MATannual).3 Contingency 
costs (CC) are calculated as 20% of the BLIC. The sum of BLIC and WCC gives the total capital 
expenditure (CapEx). 
WC = 0.035MATannual (20)
CC = 0.2BLIC (21)
WCC = WC + CC (22)
CapEx = BLIC + WCC (23)
Material prices are sourced from various vendors and are summarised in Table 4. The annual utilities 
cost (UTILannual) is calculated as 0.96 GBP kg-1 of material input; the annual waste cost (Wasteannual) is 
0.35 GBP L-1 of waste produced.3 Annual operating expenditure (OpExannual) is calculated as the sum 
of annual material (MATannual), utilities (UTILannual) and waste disposal (Wasteannual). Here, ρsolvent is the 
mother liquor solvent (Table 5). Labour costs are not considered here due to the small scale of 
production and automated nature of continuous operation. 
UTILannual = 0.96F0൫ρsolvent	+	C0൯ (24)
Wasteannual = 0.35FN (25)
OpExannual = MATannual + UTILannual + Wasteannual (26)
The total cost of the plant designs is calculated as the sum of CapEx and the sum inflation-adjusted 
OpExannual over the plant lifetime. 
Total Cost = CapEx + ෍ OpExannualሺ1 + rሻk
t
k = 1
 (27)
 
A plant-operating lifetime (t) of 20 years and an interest rate (r, accounting for inflation) of 5% are 
considered. All CapEx is assumed to occur in year 0 and operation is assumed to begin in year 1. 
 
 
7 
Table 5: Material prices of mother liquor solvents for each API continuous crystallization process. 
API Material (mother liquor solvent) Material Cost (GBP kg-1) 
Cyclosporine Acetone 0.29 
Paracetamol 
Isopropanol 0.29 
Water 0.60 
Aliskiren 
Ethyl Acetate 0.56 
Ethanol 0.61 
2.2.7 Nonlinear Optimization Formulation 
The objective function (eq. 28) of the nonlinear optimization problem is the total cost (eq. 27). The 
decision variables are the residence time and temperature of each crystallizer in the cascade, both of 
which affect the final attainable crystallization yield, process mass balances and total costs of the 
cascade design. Crystallization temperatures are constrained between -10 and 20 °C and the 
temperature of each crystallizer must be lower than or equal to the previous (eq. 29). Crystallizers of 
equal residence times are assumed for the problem formulation (eq. 30). Implementing crystallizers of 
equal volumes makes their purchase and acquirement from equipment suppliers/manufacturers 
simpler and less expensive. Additionally, the total cascade residence time is allowed a maximum of 
15 h (eq. 31) in accordance with our previous work.57 
min Total Cost (28) 
–10 °C ≤ TN ≤ … ≤ T1 ≤ 20 °C (29) 
τ1 = … = τN  (30) 
෍ τi	≤	15 h
N
i	=	1
 (31)
 
The optimization problem is solved in MATLAB using the built-in solver fmincon, implementing 
the (default) interior-point algorithm with tolerances of 10-6. The problem was solved separately for 
all combinations of API = {cyclosporine, paracetamol, aliskiren}, number of implemented 
crystallizers, N = {1, 2, 3}, and plant capacity, QAPI = {102, 103, 104} kg API per annum, i.e., 9 
problem instances in total, to avoid mixed integer problem formulations, which would increase the 
computational effort. 
Multiple initial values for decision variables have been used to ensure a unique optimal solution for 
each problem instance. The temperature and residence time of each crystallizer in series are the 
decision variables of the nonlinear optimization problem; thus, the number of decision variables for 
configurations consisting of N crystallizers = 2N. Table 6 shows the combinations of starting points 
used for varying numbers of crystallizers for each API and considered plant capacity. Each problem 
instance resulted in a unique solution, independent of the starting point. 
Table 6: Decision variable initial values for and plant capacities for different numbers of crystallizers (N). 
N Decision Variable Initial Value No. points, 
 T0 × τ0 
1 T0 = T1,0 (°C) { -5 , 0 , 5 } 9 
τ0 = τ1,0 (h) { 3 , 8 , 13 } 
2 T0 = [T1, T2]0 (°C) { [-5,-5] , [0,-5] , [10,5] , [15,15] } 20 
τ0 = [τ1, τ2]0 (h) { [3,3] , [3,6] , [3,9] , [6,3] , [9,3] } 
3 T0 = [T1, T2, T3]0 (°C) { [-5,-5,-5] , [0,-5,-5] , [5,0,0] , [10,5,5] , [15,10,10] , [15,15,15] } 24 
τ0 = [τ1, τ2, τ3]0 (h) { [3,3,3] , [3,3,6] , [3,6,3] , [6,3,3] } 
3. Results and Discussion 
Total cost minimization via nonlinear optimization was implemented for each API (cyclosporine, 
paracetamol and aliskiren), for a varying number of crystallizers (N = 1, 2, 3) and plant capacity (QAPI 
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= 102, 103, 104 kg API y-1). Minimum total cost components for all APIs for different numbers of 
implemented crystallizers and plant capacities are illustrated in Figure 3 and Tables S1-3 in the 
Supplementary Information.  
 
 
Figure 3: Minimum total cost components for each API at different plant capacities. 
3.1 Capital Expenditures (CapEx) 
Total CapEx increases with plant API capacity due to the need for larger crystallizer volumes to 
contain higher throughputs of crystallization magma. Figure 4 shows total cost components 
normalized with respect to total plant API capacity, which further illustrates the decreasing 
contribution of CapEx components to total costs. Total CapEx values are dominated by BLIC 
contributions due to the high cost of crystallization equipment (Table 4), and WCC contributions 
increase with plant capacity as it is a linear function of material requirements (eqs. 20 and 22). Both 
BLIC and WCC contributions increase with the number of implemented crystallizers, despite 
decreasing total crystallization volumes and material requirements. This is due to the cost of 
additional pumps and cooling equipment accompanying the crystallizer cascade for continuous 
operation. The nonlinear optimization formulation here is described to minimize total costs; if the 
formulations were to maximize profits or net present value (NPV), it is possible that longer residence 
times would be preferred. Formulating the objective function as NPV (for maximization) requires the 
estimation of product sales revenues. While API class sales trends have been historically increasing 
(Figure 1), future market sales variations of individual APIs and brands are unknown and cannot be 
accurately accounted for. For this reason, the objective is instead to minimize the plant total costs. 
Varying the objective function of an optimization problem can produce widely varying optimal design 
and operating parameters;65 comparison of optimization results for different objective function 
formulations is also possible, assuming availability of reliable API and brand sales prices/projections. 
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Figure 5 illustrates optimal process configurations (i.e., crystallizer operating temperatures and 
residence times corresponding to total cost minima) for each API with different numbers of 
crystallizers and API capacities considered (also listed in Tables S4-6 in the Supplementary 
Information). Crystallizer volumes increase with plant capacity to accommodate increased material 
throughputs. Increasing the number of implemented crystallizers decreases the total crystallization 
volume required. MSMPR operation assumes perfectly mixed, homogeneous crystallizer magmas 
discharging at equilibrium, and thus the crystallizer operates at the exit concentration; implementing 
multiple crystallizers in series increases product concentrations and thus increases yields, which thus 
requires smaller crystallizers for a given API and plant capacity. Total residence times for aliskiren 
are long due to the slow crystallization kinetics of the API (and hence its suitability for MSMPR 
operation) in accordance with experimental demonstrations.20 
 
 
 
Figure 4: Minimum total cost components normalized with respect to plant capacity. 
The equipment cost correlation used here is the most widely implemented and reliable available in 
the peer-reviewed literature. However, crystallizer design capacities (i.e., volumes) required for the 
considered plant capacities are at the lower end of the cost correlation application range, and thus 
purchase cost overestimation may be present. Additional uncertainty in calculated crystallizer 
purchase costs is present due to the lack of cost estimation methods for smaller crystallizer volumes 
10 
associated with lower plant capacities, e.g. cyclosporine at QAPI = 102 kg y-1 (Table S4 in the 
Supplementary Information); however, the cost correlation used here is the best available in the 
literature. 
 
 
Figure 5: Crystallizer operating temperatures and residence times corresponding to total cost minima; 
bubble diameters are proportional to crystallizer volumes. 
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3.2 Operating Expenditures (OpEx) 
Total OpEx increases with plant API capacity due to the higher required material throughputs and 
associated utilities and waste handling costs. Figure 6 shows the fractional relative minimum total cost 
component contributions for each API at varying plant capacities for one crystallizer. At lower API 
capacities, CapEx contributions are more significant; as plant capacity increases, OpEx component 
contributions become more significant, which is further illustrated by their continuing dominance over 
normalized CapEx components as plant API capacities increase (Figure 4). Utilities costs dominate 
OpEx contributions, however materials and waste handling costs become more significant with 
increasing plant capacity. 
Cyclosporine operating temperatures are above zero and decrease along the crystallizer cascade 
(Figure 5 and Table S4 in the Supplementary Information), as described in the constrained nonlinear 
optimization constraints (eq. 29). Crystallizers for paracetamol and aliskiren also decrease in 
temperature along cascades, however operate at lower temperatures. In both cases, as the number of 
implemented crystallizers is increased, operating temperatures increase and residence times decrease; 
additional costs associated with increased cooling duties and larger crystallizers are not considered 
beneficial with respect to total costs. Rigorous temperature control via high-fidelity instrumentation 
can ensure designs remain at their optimal design parameters. The implementation of Process 
Analytical Technology (PAT) is essential for the success of CPM technologies, with recent studies 
illustrating its importance in crystallization applications.66 Optimal crystallizer operating temperatures 
correspond to those required to attain minimum total costs of a design option; deviations from 
optimum design and operating parameters will lead to sub-optimal designs (i.e., higher total costs). 
3.3 Total Costs 
Minimum total costs for cyclosporine crystallization are attained when implementing one crystallizer 
only for API capacities of 102 and 103 kg API y-1 (Table S1 in the Supplementary Information); yield 
improvements associated with multiple crystallizer usage are only incremental (Table S4 in the 
Supplementary Information); thus, the associated additional BLIC costs are not beneficial. However, 
when the plant capacity is increased to 104 kg API y-1, cyclosporine crystallization has lower total 
costs when two crystallizers are implemented. At higher capacities, OpEx components dominate total 
costs, and so even incremental increases in crystallization yield and distributed cooling loads across 
crystallizers can bring cost savings benefits. 
For plant capacities of 102 and 103 kg API y-1, paracetamol crystallization is cost optimal when 
implementing one crystallizer due to incremental yield improvements attainable with multiple 
crystallizer implementation at these capacities. Implementing two crystallizers is optimal at a plant 
capacity of 104 kg API y-1 (Table S2 in the Supplementary Information); this is due to the greater 
contribution of OpEx towards total costs at increased capacities as well as the reduced total 
crystallizer volume required (Table S5 in the Supplementary Information). 
Continuous crystallization of aliskiren at a plant capacity of 102 kg API y-1 is cost optimal when 
implementing one crystallizer only; implementing two crystallizers at a capacity of 103 kg y-1 and 
three crystallizers at 104 kg y-1 is more cost effective (Table S3 in the Supplementary Information). 
The mother liquor solvent considered here (ethyl acetate:ethanol mixture) is more expensive than 
solvents for cyclosporine and paracetamol, thus material costs contribute more towards the dominant 
OpEx components (Table S6 in the Supplementary Information and Figure 6). 
For the considered APIs and number of implementable crystallizers (N = {1, 2, 3}), multiple 
crystallizer usage is favoured as capacity increases. It is likely that there is some maximum number of 
crystallizers that allow minimum total costs for capacities beyond a certain value, however this cannot 
be stated with certainty from the results presented here; this can be clarified in future work. Total cost 
minimization at higher capacities can be investigated in the described modelling framework and 
methodology. 
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Figure 6: Component contributions towards total costs when implementing one crystallizer. 
The relative effect of varying crystallization kinetics between the considered APIs varies with the 
plant capacity. For QAPI = 102 kg y-1, cyclosporine CapEx components are significantly more 
dominant than at higher capacities for this API; material costs (OpEx) are less significant at lower 
capacities and thus the effect of cyclosporine’s slow crystallization kinetics on CapEx (requiring 
longer residence times and crystallizer volumes) become more significant. CapEx component 
contributions for aliskiren are greater than those for paracetamol due to its slower crystallization 
kinetics. For both aliskiren and paracetamol, OpEx components are more significant even at QAPI = 
102 kg y-1 as these APIs both require more expensive solvent components than cyclosporine (Table 5). 
The current modelling methodology and framework allows different APIs, capacities and numbers of 
implemented MSMPR crystallizers to be considered easily, given the availability of crystallization 
kinetic parameters and API temperature-dependent solubility data in a given mother liquor solvent 
system. 
4. Conclusions 
This work has conducted total cost minimization of continuous MSMPR crystallizer cascades for 
three societally and economically important APIs widely produced by the pharmaceutical industry: 
cyclosporine, paracetamol and aliskiren. Nonlinear optimization results show that the optimal number 
of crystallizers attaining minimal total costs is dependent on plant capacity. For the considered APIs, 
implementing one crystallizer is preferred at lower capacities, whilst multiple crystallizer usage is 
preferred at higher plant capacities. This result is observed due to the increasing dominance of 
operating expenditure contributions towards total costs at increased capacities, making the benefits of 
implementing more crystallizers (enhanced yields, reduced utility loads) worth the increased capital 
expenditure of purchasing multiple crystallization units. We have illustrated the value of conducting 
technoeconomic optimization studies such as this towards the development of continuous separations 
in pursuit of economically viable end-to-end CPM plants.   
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Nomenclature and Acronyms 
Latin Letters and Acronyms 
API Active pharmaceutical ingredient 
b Crystal nucleation exponent (–) 
Bi Crystal nucleation rate (# m-3 min-1) 
BLIC Battery limits installed costs (GBP) 
Ci API concentration in product magma of MSMPR i (g mL-1) 
Ci,sat API saturation concentration at Ti (g mL-1) 
C0 Mother liquor API concentration of the fresh feed stream (g mL-1) 
CapEx Capital expenditure (GBP) 
CC Contingency costs (GBP) 
CEPCI Chemical engineering plant cost index 
CPM Continuous pharmaceutical manufacturing 
Eag Crystal growth activation energy (J mol-1) 
f Correction factor in eq. 15 
Fi Volumetric flowrate of stream i (mL min-1) 
F0 Volumetric flowrate of the fresh feed stream (mL min-1) 
FOB Free-on-Board Costs (GBP) 
g Crystal growth exponent (–) 
Gi Crystal linear growth rate (m min-1) 
IEC Installed equipment costs (GBP) 
kb0 Pre-exponential factor for crystal nucleation (# m-3 min-1) 
kg0 Pre-exponential factor for crystal growth (m min-1) 
kv Crystal volume shape factor (–) 
L Crystal characteristic length (m) 
Mi MSMPR slurry density (g mL-1) 
MATannual Annual material costs (GBP y-1) 
MSMPR Mixed suspension, mixed product removal crystallizer 
N Total number of MSMPRs in crystallization cascade 
n Exponent in eq. 15 
ni Crystal population density (# m-3 m-1) 
14 
ni0 Nuclei population density (# m-3 m-1) 
NPV Net present value 
ODE Ordinary differential equation 
OpExannual Annual operating expenditure (GBP y-1) 
Pj Equipment purchase cost at capacity j (GBP) 
PAT Process Analytical Technology 
PPI Process piping and instrumentation costs (GBP) 
QAPI Plant API production capacity (kg y-1) 
R Universal gas constant (= 8.314 J mol-1 K-1) 
r Interest rate (%) 
Sj Capacity of equipment (varying units) 
t Plant operation lifetime (y) 
Ti Operating temperature of MSMPR i (°C) 
Ti,opt Operating temperature of MSMPR i (°C) corresponding to minimum total costs  
T0 Vector of initial crystallizer temperatures (°C) 
TPPC Total physical plant cost (GBP) 
UTILannual Annual utilities costs (GBP y-1) 
Vi Volume of MSMPR i (mL) 
Vi,opt Volume of MSMPR i (mL) corresponding to minimum total costs 
VTOT,opt Total volume of all crystallizers in series (mL) corresponding to minimum total costs 
Wasteannual Annual waste disposal cost (GBP y-1) 
WC Working capital costs (GBP) 
WCC Working capital and contingency costs (GBP) 
Ycryst Crystallisation yield (%) 
  
Greek Letters  
ρAPI API solid crystal density (g cm-3) 
ρsolvent Mother liquor solvent density at Ti (g mL-1) 
τi Residence time in MSMPR i (min) 
τi,opt Residence time in MSMPR i (min) corresponding to minimum total costs 
τ0 Vector of initial crystallizer residence times (h) 
τTOT,opt Total cascade residence time (min) corresponding to minimum total costs 
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